<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695732</url>
  </required_header>
  <id_info>
    <org_study_id>CSY-LC02-2016</org_study_id>
    <nct_id>NCT02695732</nct_id>
  </id_info>
  <brief_title>The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding</brief_title>
  <official_title>Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ShuGuang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gongli Hospital, School of Medicine, The Second Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of Carvedilol and endoscopic therapy in Primary
      Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized controlled trial. Patients randomly enter into two treatment
      groups: 1)the Carvedilol group and 2)the endoscopy group. Treatment allocation is by block
      randomization, with an two-to-one ratio for Carvedilol and endoscopy. The results are
      concealed in opaque envelopes. The dose of Carvedilol is titrated according to systolic
      arterial blood pressure (ABPsys) and heart rate (HR). Doses are increased every 7 days until
      ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm. Carvedilol is started at a
      dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d. Patients receiving endoscopic
      therapy every 4 weeks until eradication of varices. Patients will come for clinic visit every
      6 months, receiving laboratory tests and endoscopic examinations, and events of primary and
      secondary outcomes will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding rate</measure>
    <time_frame>through study completion，an average of 18 months</time_frame>
    <description>The investigators observe the variceal bleeding events during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>through study completion，an average of 18 months</time_frame>
    <description>The investigators observe the mortality events during the study due to variceal bleeding, hepatic encephalopathy, liver failure, hepatic cellular carcinoma, hepatic-renal syndrome and spontaneous bacterial peritonitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>through study completion，an average of 18 months</time_frame>
    <description>The investigators observe any severe adverse events caused by drug or endoscopic treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">792</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Esophageal and Gastric Varices</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carvedilol，6.25mg-12.5mg/d,oral,6-36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endoscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>endoscopy，every 4 weeks until eradication of varices</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <other_name>JinLuo</other_name>
    <other_name>LvDao</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>endoscopy</intervention_name>
    <description>Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.</description>
    <arm_group_label>endoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the presence of severe esophageal and gastric varices at upper gastrointestinal
             endoscopy without a previous haemorrhage

          -  a diagnosis of liver cirrhosis based on histology, clinical or imaging manifestation

        Exclusion Criteria:

          -  age greater than 80 years old or younger than 18 years old

          -  non-cirrhotic portal hypertension

          -  contraindications to NSBB including bronchospasm, severe bradycardia, severe heart
             failure, acute pulmonary edema, atrioventricular block and so on

          -  ABPsys less than 95 mmHg or HR less than 50 bpm

          -  prior treatment for prevention of bleeding from EGV

          -  presence of spontaneous bacterial peritonitis or other severe infections

          -  presence of hepatorenal syndrome

          -  uncontrolled hepatic encephalopathy

          -  presence of refractory ascites

          -  pregnancy

          -  presence of portosystemic shunt or portal cavernous transformation

          -  refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyao Chen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiyao Chen, Professor</last_name>
    <phone>86-13601767310</phone>
    <email>chen.shiyao@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chu Liu, doctor</last_name>
      <phone>86-15201928343</phone>
      <email>09301010159@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Shiyao Chen, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Shiyao Chen</investigator_full_name>
    <investigator_title>Director of department of Gastroenterology, Zhongshan Hospital</investigator_title>
  </responsible_party>
  <keyword>Esophageal and Gastric Varices</keyword>
  <keyword>Primary Prophylaxis</keyword>
  <keyword>Carvedilol</keyword>
  <keyword>Endoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

